IRMD

IRadimed Corp

Add to Watchlist

Advanced Chart

53.700

+0.680(+1.280%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

54.1399

Open

53.050

VWAP

53.49

Vol

20.06K

Mkt Cap

682.80M

Low

53.000

Amount

1.07M

EV/EBITDA(TTM)

27.30

Total Shares

12.66M

621.92M

EV/OCF(TTM)

24.27

P/S(TTM)

9.25

IRadimed Corporation develops, manufactures, markets and distributes magnetic resonance imaging (MRI) compatible medical devices and accessories and services. Its MRidium 3860+ MRI Compatible IV infusion pump system provides non-magnetic Intravenous (IV) infusion pump system that is specifically designed for safe use during MRI procedures. Its MRidium MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor with non-ferrous parts and other special features to deliver anesthesia safely and predictably and other IV medications or fluids during various MRI procedures. Its IRadimed 3880 MRI Compatible patient vital signs monitoring system has been designed with non-magnetic components and other features to monitor a patient’s vital signs safely and accurately during various MRI procedures. The Company sells its products primarily to hospitals and acute care facilities. The IRADIMED 3880 system operates dependably in magnetic fields up to 30,000 gausses.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q2

FY2025Q1

19.90M

+8.61%

19.81M

+10.47%

19.33M

+9.85%

Estimates Revision

The market is revising No Change the revenue expectations for IRADIMED CORPORATION (IRMD) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -10.96%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-10.96%

In Past 3 Month

2 Analyst Rating

32.22% Upside

Wall Street analysts forecast IRMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IRMD is 71.00 USD with a low forecast of 70.00 USD and a high forecast of 72.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

32.22% Upside

Current: 53.700

Low

70.00

Averages

71.00

High

72.00

32.22% Upside

Current: 53.700

Low

70.00

Averages

71.00

High

72.00

Roth MKM

Jason Wittes

Strong Buy

Reiterates

$60 → $72

2025-02-14

Reason

Roth MKM

Jason Wittes

Price Target

$60 → $72

2025-02-14

Reiterates

Strong Buy

Reason

Roth MKM raised the firm's price target on iRadimed to $72 from $60 and keeps a Buy rating on the shares. The company reported solid Q4 revenue of $19.4M, representing an 11% y/y increase while beating the firm's estimate and consensus of $19.1M as well as previously issued guidance of $19.2M-$19.4M for FY24, the analyst tells investors in a research note. Monitoring system bookings also improved in Q4, signaling early traction from iRadimed's renewed salesforce focus on this product category, the firm adds.

Roth MKM

Jason Wittes

Strong Buy

Maintains

$65 → $60

2024-08-02

Reason

Roth MKM

Jason Wittes

Price Target

$65 → $60

2024-08-02

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for IRadimed Corp (IRMD.O) is 33.19, compared to its 5-year average forward P/E of 40.70. For a more detailed relative valuation and DCF analysis to assess IRadimed Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

40.70

Current PE

33.19

Overvalued PE

54.90

Undervalued PE

26.51

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

8.17

Current PS

8.49

Overvalued PS

9.60

Undervalued PS

6.74